Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obexelimab phase 2 placebo-controlled study in systemic lupus erythematosus
jRCT2011240033Phase 2Recruiting
- Sponsor
- Zenas BioPharma
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Obexelimab with Placebo (2 arms). Primary endpoint: BICLA response. Started Jan 2025; status: recruiting.
02
Drugs
obexelimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2011240033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240033.